TCGA-22-1011-01A-01R-0692-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- APICAL_SURFACE+0.380
- ALLOGRAFT_REJECTION+0.340
- INFLAMMATORY_RESPONSE+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- HEDGEHOG_SIGNALING+0.250
- ANDROGEN_RESPONSE+0.240
- TNFA_SIGNALING_VIA_NFKB+0.230
- HYPOXIA+0.210
- G2M_CHECKPOINT+0.190
- KRAS_SIGNALING_UP+0.180
Top 10 suppressed
- MYC_TARGETS_V2-0.440
- OXIDATIVE_PHOSPHORYLATION-0.300
- ADIPOGENESIS-0.210
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.210
- MYC_TARGETS_V1-0.190
- UV_RESPONSE_UP-0.170
- DNA_REPAIR-0.160
- INTERFERON_ALPHA_RESPONSE-0.150
- XENOBIOTIC_METABOLISM-0.110
- SPERMATOGENESIS-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SAMN03290894 | — | — | 0.769 |
| 2 | TCGA-60-2704-01A-11R-2045-07 | — | cohortSQ1 | 0.755 |
| 3 | BS_KBT7MQ6H | EPN | Supratentorial EPN | 0.737 |
| 4 | TCGA-22-4609-01A-21R-2125-07 | — | cohortSQ1 | 0.736 |
| 5 | d719788d-0c64-4488-bb84-ab5536d31a03 | — | — | 0.728 |
| 6 | TCGA-HD-7753-01A-11R-2081-07 | — | — | 0.727 |
| 7 | ffe7358d-31b2-4d92-93eb-0a88abaf2dca | — | — | 0.721 |
| 8 | SRR17866851 | — | — | 0.719 |
| 9 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.712 |
| 10 | MNG3 | — | — | 0.709 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| APICAL_SURFACE | 0.380 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.230 | Inavolisib | — uncovered |
| HYPOXIA | 0.210 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.160 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.150 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.140 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |